? There has been growing evidence that bone marrow derived stem cells injected into areas of damaged myocardium prevent deleterious remodeling of the post-myocardial infarcted heart. However, the survival and function of these bone marrow derived stem cells (BMC) once injected are not known. Therefore, the main goals of this proposal are to use newly developed molecular probes from our laboratory to track BMC and to understand the biology of integration and the cellular fate of BMC in a large animal model of myocardial infarction and remodeling. These novel molecular probes generate contrast simultaneously for both magnetic resonance imaging (MRI) and near-infrared (NIR) fluorescent optical imaging. MRI permits BMC to be identified in the normal and diseased hearts of large animals over time, non-invasively, and without sacrifice of the animal. NIR fluorescent optical imaging provides high sensitivity, and in some cases single cell sensitivity, which can be used for intraoperative physiological studies and for histological correlation with other markers of cardiomyocyte function.
In Specific Aim 1 we will test and validate novel MRI/optical dual-modality contrast agents already developed by our laboratories in isolated bone marrow cells from pigs.
In Specific Aim 2 we will use an established non-invasive catheter technique or use a surgical open-chested technique under NIRF guidance to deliver autologous stem cells in normal swine left ventricles.
In Specific Aim 3 we will use an established non-invasive catheter technique or use a surgical open-chested technique under NIRF guidance to deliver autologous stem cells in a swine model of myocardial infarction. Our ability to distinguish and retrieve implanted cells will also enable us to directly assess the molecular and functional status of BMC following cardiomyogenic differentiation. The knowledge gained from this proposal will contribute to the usage of newly developed dual probes with the capability of being visible at both near-infrared and also by magnetic resonance imaging and also will enhance our understanding of the cellular fate of implanted BMCs and their cellular function following cardiomyogenic-differentiation. This will ultimately advance the field of stem cell biology and cell-based therapies for the treatment of cardiovascular diseases. (End of Abstract) ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL078691-03
Application #
7111071
Study Section
Special Emphasis Panel (ZHL1-CSR-K (S1))
Program Officer
Pandit, Sunil
Project Start
2004-09-22
Project End
2007-08-31
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
3
Fiscal Year
2006
Total Cost
$656,495
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Hadri, Lahouaria; Kratlian, Razmig G; Benard, Ludovic et al. (2013) Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension. Circulation 128:512-23
Lompré, A-M; Hadri, L; Merlet, E et al. (2013) Efficient transduction of vascular smooth muscle cells with a translational AAV2.5 vector: a new perspective for in-stent restenosis gene therapy. Gene Ther 20:901-12
Lipskaia, L; Hadri, L; Le Prince, P et al. (2013) SERCA2a gene transfer prevents intimal proliferation in an organ culture of human internal mammary artery. Gene Ther 20:396-406
Jessup, Mariell; Greenberg, Barry; Mancini, Donna et al. (2011) Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124:304-13
Hadri, Lahouaria; Bobe, Regis; Kawase, Yoshiaki et al. (2010) SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. Mol Ther 18:1284-92
Lipskaia, Larissa; Chemaly, Elie R; Hadri, Lahouaria et al. (2010) Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure. Expert Opin Biol Ther 10:29-41
Peña, James R; Szkudlarek, Ariani C; Warren, Chad M et al. (2010) Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 49:993-1002
Poller, Wolfgang; Hajjar, Roger; Schultheiss, Heinz-Peter et al. (2010) Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure. Cardiovasc Res 86:353-64
Suckau, Lennart; Fechner, Henry; Chemaly, Elie et al. (2009) Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 119:1241-52
Ly, Hung Q; Hoshino, Kozo; Pomerantseva, Irina et al. (2009) In vivo myocardial distribution of multipotent progenitor cells following intracoronary delivery in a swine model of myocardial infarction. Eur Heart J 30:2861-8

Showing the most recent 10 out of 34 publications